Biolex Therapeutics, Inc. has published results for a Phase 1 clinical trial of Locteron®, a controlled-release drug to treat chronic hepatitis C, in the Journal of Interferon & Cytokine Research.
In Phase 1 results, Locteron showed a reduction in the severity and duration of certain side effects, such as flu-like symptoms, that are common in currently used medication. The drug also allowed dosing once every two weeks, an improvement over current drugs that require weekly dosing.
Locteron®, under joint development with OctoPlus N.V, is the lead product candidate for Biolex which is based in Pittsboro, NC. It is in Phase 2 clinical trials and is the only controlled-release interferon alfa currently in clinical development for the treatment of chronic hepatitis C.
Biolex is a clinical-stage biopharmaceutical company that uses its patented LEX System(SM) to develop hard-to-make therapeutic proteins and to optimize monoclonal antibodies. The LEX System uses technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates.